DK0533280T3 - New medical use of tachykinin antagonists - Google Patents
New medical use of tachykinin antagonistsInfo
- Publication number
- DK0533280T3 DK0533280T3 DK92202831T DK92202831T DK0533280T3 DK 0533280 T3 DK0533280 T3 DK 0533280T3 DK 92202831 T DK92202831 T DK 92202831T DK 92202831 T DK92202831 T DK 92202831T DK 0533280 T3 DK0533280 T3 DK 0533280T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- sup
- antagonists
- medical use
- tachykinin antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists, processes for their preparation, pharmaceutical compositions containing them and their medical use. whereinR represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide;R<sup>1</sup> is selected from halogen atoms and C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl, and S(0)<sub>n</sub>C<sub>1-4</sub>alkyl groups;R<sup>2</sup> and R<sup>3</sup>, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, trifluoromethyl and cyano groups;n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919120172A GB9120172D0 (en) | 1991-09-20 | 1991-09-20 | Chemical compounds |
GB929202839A GB9202839D0 (en) | 1992-02-11 | 1992-02-11 | Chemical compounds |
GB929204151A GB9204151D0 (en) | 1992-02-27 | 1992-02-27 | Medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0533280T3 true DK0533280T3 (en) | 2001-01-02 |
DK0533280T4 DK0533280T4 (en) | 2005-02-28 |
Family
ID=27265859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92202831T DK0533280T4 (en) | 1991-09-20 | 1992-09-16 | New medical use of tachykinin antagonists |
Country Status (14)
Country | Link |
---|---|
US (7) | US5360820A (en) |
EP (4) | EP1082959A1 (en) |
JP (1) | JP3020757B2 (en) |
KR (1) | KR100233323B1 (en) |
AT (1) | ATE195867T1 (en) |
AU (1) | AU657996B2 (en) |
CA (1) | CA2078578C (en) |
DE (1) | DE69231395T3 (en) |
DK (1) | DK0533280T4 (en) |
ES (1) | ES2149767T5 (en) |
GR (1) | GR3034682T3 (en) |
IL (1) | IL103214A (en) |
PT (1) | PT533280E (en) |
TW (1) | TW311139B (en) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA27776C2 (en) * | 1991-05-31 | 2000-10-16 | Пфайзер Інк. | Quinuclidine derivatives, pharmaceutically acceptable saults thereof which are substance p receptor antagonists in mammals, pharmaceutical composition possessing antagonist activity on substance p in mammals |
EP1082959A1 (en) | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
US5444074A (en) * | 1992-04-15 | 1995-08-22 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
US5637699A (en) * | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
GB9216911D0 (en) * | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US5837711A (en) * | 1992-10-28 | 1998-11-17 | Pfizer Inc. | Substituted quinuclidines as substance P antagonists |
ES2096312T3 (en) * | 1992-11-12 | 1997-03-01 | Pfizer | QUINUCLIDINE DERIVATIVE AS ANTAGONIST OF THE SUBSTANCE P. |
FR2700472B1 (en) | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Synergizing association having an antagonistic effect on the NK1 and NK2 receptors. |
GB9305593D0 (en) * | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
ATE155456T1 (en) | 1993-05-28 | 1997-08-15 | Pfizer | METHOD FOR THE PRODUCTION AND OPTICAL RESOLUTION OF 2-PHENYL-3-AMINOPIPERIDINE |
US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
FR2710842B1 (en) * | 1993-10-07 | 1995-11-24 | Rhone Poulenc Rorer Sa | New therapeutic application of perhydroisoindole derivatives. |
EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Pharmaceutical agents for treatment or prevention of sunburn. |
US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5491140A (en) * | 1994-06-30 | 1996-02-13 | Eli Lilly And Company | Naphthyl tachykinin receptor antagonists to treat physiological conditions |
MX9700271A (en) | 1994-07-12 | 1997-05-31 | Lilly Co Eli | Heterocyclic tachykinin receptor antagonists. |
CA2205016A1 (en) * | 1994-11-10 | 1996-05-23 | Hans-Jurgen Ernst Hess | Nk-1 receptor antagonists for the treatment of eye disorders |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
CA2206119C (en) * | 1994-12-12 | 2008-05-13 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5565568A (en) * | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
WO1996041633A1 (en) * | 1995-06-08 | 1996-12-27 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
WO1996041631A1 (en) * | 1995-06-09 | 1996-12-27 | Eli Lilly And Company | Methods of treating cold and allergic rhinitis |
GB9513972D0 (en) * | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
FR2738742B1 (en) * | 1995-09-19 | 1997-11-14 | Oreal | USE OF AT LEAST ONE VICHY THERMAL WATER AS AN ANTAGONIST OF SUBSTANCE P |
TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
GB9524104D0 (en) * | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
JP2000514047A (en) * | 1996-06-26 | 2000-10-24 | ワーナー―ランバート・コンパニー | Use of tachykinin antagonists for the manufacture of a medicament for the treatment of emesis |
ATE265209T1 (en) * | 1996-07-17 | 2004-05-15 | Merck & Co Inc | ALTERING THE CIRCADIC RHYTHM WITH NON-PEPTID NEUROKININ-1 RECEPTOR ANTAGONISTS |
MX9706944A (en) * | 1996-09-12 | 1998-08-30 | Pfizer | Quinuclidines substituted with tetrazolyl as antagonist of the substance p. |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5773458A (en) * | 1996-10-30 | 1998-06-30 | American Home Products Corporation | 1-azabicycloheptane derivatives |
CA2273853A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating cognitive disorders |
US6114315A (en) * | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
CA2273856A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
JP2001504853A (en) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | Use of an NK-1 receptor antagonist for the treatment of a substance use disorder |
US6613765B1 (en) | 1996-12-02 | 2003-09-02 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
JP2001507678A (en) * | 1996-12-02 | 2001-06-12 | メルク シヤープ エンド ドーム リミテツド | Use of an NK-1 receptor antagonist for the treatment of movement disorders |
US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
JP2001504851A (en) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | Use of an NK-1 receptor antagonist for the treatment of sexual dysfunction |
US6100256A (en) * | 1996-12-02 | 2000-08-08 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptors antagonists for treating schizophrenic disorders |
US5846973A (en) * | 1997-05-23 | 1998-12-08 | Eli Lilly And Company | Methods of treating pulmonary hypertension |
GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
AU738047B2 (en) * | 1997-08-04 | 2001-09-06 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating mania |
CA2298702A1 (en) * | 1997-08-06 | 1999-02-18 | Eli Lilly And Company | 2-acylaminopropanamines as tachykinin receptor antagonists |
WO1999007677A1 (en) | 1997-08-06 | 1999-02-18 | Eli Lilly And Company | 2-acylaminopropanamines as tachykinin receptor antagonists |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
US6271230B1 (en) | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
US6087348A (en) * | 1997-12-01 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating stress disorders |
WO1999059583A1 (en) * | 1998-05-18 | 1999-11-25 | Merck & Co., Inc. | Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia |
GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
AU1409100A (en) * | 1998-11-27 | 2000-06-19 | Takeda Chemical Industries Ltd. | Drugs |
IL133077A0 (en) * | 1999-01-29 | 2001-03-19 | Pfizer Prod Inc | Azithromycin combination for emesis control in dogs |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
RU2309953C2 (en) | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines, pharmaceutical composition and method for treatment based on thereof |
GB9927125D0 (en) | 1999-11-16 | 2000-01-12 | Univ Reading The | Placental human neurokinin B precursor |
TR200302077T4 (en) * | 1999-11-29 | 2004-01-21 | F. Hoffmann-La Roche Ag | 2- (3,5-Bis-Trifluoromethyl-phenyl) -N-methyl-N- (6-morphonyl-4-yl-4-O-tolyl-pyridin-3-yl) -isobutyramide |
KR100821410B1 (en) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
EP1205855A3 (en) * | 2000-11-10 | 2006-01-25 | Masae Yanagi | Data managing method, data managing system, data managing apparatus, data handling apparatus, computer program, and recording medium |
GB0108594D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
WO2003018586A1 (en) * | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease |
EP1297826A1 (en) * | 2001-09-27 | 2003-04-02 | Menarini Ricerche S.p.A. | Nasal pharmaceutical compositions containing a NK-2 antagonist |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
AU2003244455A1 (en) * | 2002-02-08 | 2003-09-02 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
CA2392486A1 (en) | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
AR049419A1 (en) * | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | HYDROXI-6-PHENYLPHENANTRIDINES REPLACED WITH HETEROCICLYL |
BRPI0508481A (en) * | 2004-03-10 | 2007-07-31 | Altana Pharma Ag | -substituted hydroxy-6-phenylenanthridines and their use as pde4 inhibitors |
ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
BRPI0606187A2 (en) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | tablets with improved drug substance dispersibility |
ES2382814T3 (en) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2057151A4 (en) * | 2006-08-28 | 2010-07-21 | Hetero Drugs Ltd | Process for purification of aprepitant |
PL2124556T3 (en) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Pharmaceutical compositions |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
BRPI0806245B1 (en) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compounds of formula i and their uses |
KR20090112722A (en) | 2007-01-24 | 2009-10-28 | 글락소 그룹 리미티드 | Pharmaceutical compositions comprising 3,5-diamino-6-2,3-dichl0rophenyl-1,2,4-triazine or r--2,4-diamino-5-2,3-dichlorophenyl-6-fluoromethyl pyrimidine and an nk1 |
AR066267A1 (en) * | 2007-04-24 | 2009-08-05 | Takeda Pharmaceutical | PIPERIDINE DERIVATIVES AS AN TAGIQUININE RECEPTOR ANTAGONISTS |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
AR071997A1 (en) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
KR20120034644A (en) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
CN102638982B (en) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
JP2014514321A (en) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | Insulin-like growth factor 1 receptor inhibitor |
EP2729147B1 (en) | 2011-07-04 | 2017-09-06 | IRBM - Science Park S.p.A. | Nk-1 receptor antagonists for treating corneal neovascularisation |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
ES2798103T3 (en) | 2012-07-06 | 2020-12-09 | Pharmathen Sa | Stable injectable pharmaceutical composition of neurokinin-1 receptor antagonist and procedure for its preparation |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
MX363243B (en) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Compositions and methods for treating cancer. |
RU2690663C2 (en) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Substituted imidazopyridines as hdm2 inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2017021880A1 (en) | 2015-08-03 | 2017-02-09 | Leiutis Pharmaceuticals Pvt Ltd | Liquid formulations of fosaprepitant |
US9913853B2 (en) | 2015-11-03 | 2018-03-13 | Cipla Limited | Stabilized liquid fosaprepitant formulations |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
EP3672964A4 (en) | 2017-08-21 | 2021-05-26 | Leiutis Pharmaceuticals Pvt. Ltd. | Novel triple combination formulations for antiemetic therapy |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
RU2020131446A (en) | 2018-02-26 | 2022-03-28 | Оспедале Сан Раффаэле С.Р.Л. | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF EYE PAIN |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP4117673A1 (en) | 2020-03-11 | 2023-01-18 | Ospedale San Raffaele S.r.l. | Treatment of stem cell deficiency |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048058A (en) * | 1975-08-13 | 1977-09-13 | Standard Oil Company (Indiana) | Methods to be used in reforming processes employing multi-metallic catalysts |
US4066772A (en) * | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
US4175129A (en) * | 1975-07-21 | 1979-11-20 | Janssen Pharmaceutica N.V. | Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives |
US4126688A (en) * | 1976-05-17 | 1978-11-21 | Janssen Pharmaceutica N.V. | Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives |
GB2100259B (en) | 1981-06-13 | 1984-10-31 | Merrell Toraude & Co | Treatment of migraine with tropyl benzoate derivatives |
FR2557110B1 (en) | 1983-12-23 | 1989-11-24 | Sandoz Sa | NOVEL CYCLIC AMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
GB8401888D0 (en) | 1984-01-25 | 1984-02-29 | Glaxo Group Ltd | Heterocyclic compounds |
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
DE3650772T2 (en) * | 1985-04-27 | 2003-04-03 | Hoffmann La Roche | Derivatives of indazole-3-carboxamide and -3-carboxylic acid |
GB8516083D0 (en) | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
ES2053451T3 (en) | 1986-01-07 | 1994-08-01 | Beecham Group Plc | A PROCEDURE FOR THE PREPARATION OF A COMPOUND THAT HAS USEFUL PHARMACOLOGICAL PROPERTIES. |
US4906755A (en) * | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
US4839465A (en) * | 1987-01-20 | 1989-06-13 | Sterling Drug Inc. | Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof |
FR2610323B1 (en) * | 1987-02-04 | 1989-06-23 | Delalande Sa | ENANTIOMERS OF ABSOLUTE CONFIGURATION OF AMINO-3 QUINUCLIDINE AMIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION |
DE3711335A1 (en) | 1987-04-03 | 1988-10-20 | Merck Patent Gmbh | AMINO ACID DERIVATIVES |
US5360800A (en) * | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
JPH01199575A (en) | 1988-02-04 | 1989-08-10 | Rikagaku Kenkyusho | Novel cyclomaltodextrin-glucano transferase and production thereof |
GB8805269D0 (en) * | 1988-03-04 | 1988-04-07 | Glaxo Group Ltd | Medicaments |
GB8807246D0 (en) | 1988-03-25 | 1988-04-27 | Merck Sharp & Dohme | Therapeutic agents |
EP0363085A3 (en) * | 1988-10-03 | 1991-03-27 | Beecham Group Plc | Novel compounds |
MX18467A (en) * | 1988-11-23 | 1993-07-01 | Pfizer | THERAPEUTIC AGENTS OF QUINUCLIDINES |
US4920227A (en) * | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Benzobicyclic carboxamide 5-HT3 antagonists |
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
EP0412798A3 (en) * | 1989-08-08 | 1992-07-01 | Merck Sharp & Dohme Ltd. | Substituted pyridines, their preparation, formulations and use in dementia |
IE77033B1 (en) | 1989-08-16 | 1997-11-19 | Univ Tulane | Substance P antagonists |
IE903957A1 (en) * | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
FR2654725B1 (en) * | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | NEW ISOINDOLONE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU218654B (en) * | 1989-11-28 | 2000-10-28 | Syntex (U.S.A.) Inc. | Tricyclic compounds, pharmaceutical preparatives containing such compounds and process for their production |
UA41251C2 (en) * | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Hydrogenated nitrogen-containing heterocyclic substances, piperidine derivatives, pharmaceutical composition and method for inhibiting activity of p substance |
US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
WO1991012266A1 (en) | 1990-02-15 | 1991-08-22 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound |
DE4007869A1 (en) | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | AMINOSAEUREDERIVATE |
IT1240643B (en) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN |
EP0550635B1 (en) * | 1990-09-28 | 1995-04-19 | Pfizer Inc. | Fused ring analogs of nitrogen containing nonaromatic heterocycles |
GB9023116D0 (en) | 1990-10-24 | 1990-12-05 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
DE4034829A1 (en) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | CYCLOPEPTIDE |
DE69220258T2 (en) * | 1991-02-11 | 1997-12-18 | Merck Sharp & Dohme | Azabicyclic compounds, pharmaceutical preparations containing them and their therapeutic use |
BR9205807A (en) | 1991-03-26 | 1994-06-28 | Pfizer | Stereo-selective preparation of substituted piperidines |
KR0154882B1 (en) | 1991-06-20 | 1998-11-16 | 알렌 제이. 스피겔 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles |
TW202432B (en) | 1991-06-21 | 1993-03-21 | Pfizer | |
CA2110513A1 (en) | 1991-07-05 | 1993-01-21 | Christopher J. Swain | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
EP1082959A1 (en) * | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
US6048859A (en) * | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
GB9305718D0 (en) | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
JP3503768B2 (en) * | 1995-01-06 | 2004-03-08 | 関西電力株式会社 | Control equipment for trench excavator |
TW458774B (en) | 1995-10-20 | 2001-10-11 | Pfizer | Antiemetic pharmaceutical compositions |
ZA985765B (en) * | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
-
1992
- 1992-09-16 EP EP00203202A patent/EP1082959A1/en not_active Withdrawn
- 1992-09-16 AT AT92202831T patent/ATE195867T1/en active
- 1992-09-16 EP EP92202831A patent/EP0533280B2/en not_active Expired - Lifetime
- 1992-09-16 DK DK92202831T patent/DK0533280T4/en active
- 1992-09-16 EP EP99200338A patent/EP0919245A3/en not_active Withdrawn
- 1992-09-16 ES ES92202831T patent/ES2149767T5/en not_active Expired - Lifetime
- 1992-09-16 DE DE69231395T patent/DE69231395T3/en not_active Expired - Lifetime
- 1992-09-16 PT PT92202831T patent/PT533280E/en unknown
- 1992-09-16 EP EP99200337A patent/EP0916346A3/en not_active Withdrawn
- 1992-09-18 JP JP4275091A patent/JP3020757B2/en not_active Expired - Lifetime
- 1992-09-18 KR KR1019920017021A patent/KR100233323B1/en not_active IP Right Cessation
- 1992-09-18 IL IL10321492A patent/IL103214A/en not_active IP Right Cessation
- 1992-09-18 US US07/946,635 patent/US5360820A/en not_active Expired - Lifetime
- 1992-09-18 AU AU24583/92A patent/AU657996B2/en not_active Expired
- 1992-09-18 CA CA002078578A patent/CA2078578C/en not_active Expired - Lifetime
- 1992-09-29 TW TW081107713A patent/TW311139B/zh not_active IP Right Cessation
-
1994
- 1994-06-30 US US08/269,079 patent/US5538982A/en not_active Expired - Lifetime
-
1995
- 1995-12-27 US US08/579,294 patent/US5798363A/en not_active Expired - Lifetime
-
1996
- 1996-09-03 US US08/706,836 patent/US6326383B1/en not_active Expired - Fee Related
-
1999
- 1999-05-14 US US09/311,570 patent/US6191139B1/en not_active Expired - Lifetime
-
2000
- 2000-10-26 GR GR20000402369T patent/GR3034682T3/en unknown
-
2001
- 2001-11-05 US US09/985,679 patent/US7214692B2/en not_active Expired - Fee Related
-
2004
- 2004-11-18 US US10/990,462 patent/US7342028B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0533280T3 (en) | New medical use of tachykinin antagonists | |
WO1993014084A3 (en) | Piperidine derivatives | |
HUP9901820A2 (en) | 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production | |
AR033306A1 (en) | COMPOUNDS | |
LU92209I2 (en) | Clevidipine in any form providing protection from the basic patent | |
FI931600A0 (en) | PYRIDINER OCH PYRIDIN-N-OXIDDERIVAT AV DIARYLMETHYLPIPERIDINER ELLER PIPERAZINER, OCH FOERENINGAR OCH FOERFARANDE FOER DERAS ANVAENDNING | |
AU4306796A (en) | Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs | |
KR970704435A (en) | Use of Heterocyclic Compounds as Dopamine-D Ligands (Use of Heterocyclic Compounds as Dopamine-D Ligands) | |
MX9806255A (en) | Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs. | |
KR890700125A (en) | New benzimidazole derivatives, preparation method thereof and pharmaceutical composition containing the compound | |
ES8506616A1 (en) | N-aryl-alpha-amino-carboxamides. | |
ES481129A1 (en) | New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation. | |
AR015446A1 (en) | ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDS | |
ATE21900T1 (en) | PYRIMIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
EA200300044A1 (en) | NEW SUBSTITUTED PHTHALIDES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
HUP0003962A2 (en) | Quinuclidinium compounds process for preparing thereof, pharmaceutical compositions comprising thereof, their use, and their intermediates | |
TR199801774T2 (en) | Use of 4-phenyl-3, 6-dihydro-2H-pyridyl derivatives as NMDA receptor subtype blockers. | |
ES8602723A1 (en) | 2-(n-pyrrolidino)-3-isobutoxy-n-phenyl-substituted n-benzylpropyl amines, their preparation and their pharmaceutical use | |
NO165593C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW TETRACYCLIC INDOLIDATE DERIVATIVES. | |
NO166125C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE AROYL-SUBSTITUTED DIHYDRO-1,4-TIAZINES. | |
FR2823749B1 (en) | PHENYL- AND PYRIDYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EP0461264A4 (en) | Ethynylphenyl derivative, production thereof, and remedy for diseases of circulatory organs containing the same as active ingredient | |
SE8504708L (en) | NEW NUCLEOSIDE DERIVATIVES WITH ANTIHERPATIVE PROPERTIES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND PROCEDURE FOR THE PREPARATION OF THE ACTIVE INGREDIENTS | |
SE8802162L (en) | NEW AMINOACYLATES OF GLYCEROL ACETAL | |
RU95108218A (en) | Tricycle heterocyclic sulfonamides and sulfoether derivatives, process for preparation thereof, medicinal composition, method or medical treatment and prophylaxis of new formations |